VRCA vs. TNXP, ALLO, INZY, ALDX, CADL, ACB, SGMT, IMMP, CRDF, and FENC
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Cardiff Oncology (CRDF), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs. Its Competitors
Verrica Pharmaceuticals (NASDAQ:VRCA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.
Verrica Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.
Verrica Pharmaceuticals has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Verrica Pharmaceuticals' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.
In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 2 mentions for Tonix Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Tonix Pharmaceuticals' score of 0.16 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Verrica Pharmaceuticals has higher earnings, but lower revenue than Tonix Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 835.45%. Tonix Pharmaceuticals has a consensus target price of $585.00, indicating a potential upside of 1,139.67%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Verrica Pharmaceuticals.
Summary
Tonix Pharmaceuticals beats Verrica Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 7/17/2025 by MarketBeat.com Staff
Free VRCA Stock Alerts